Bristol-myers Squibb Compnay

Boehringer Ingelheim International Gmbh

Viiv Healthcare UK (no.5) Limited

Syros Pharmaceuticals, Inc.

Viiv Healthcare UK Limited

Bristol-myers Squibb Holdings Ireland

Clint A James

Edward H Ruediger

Nicholas A Meanwell

Daniel H Deon

Carol Bachand

Rico Lavoie

Lawrence G Hamann

Andrew Charles Good

Makonen Belema

David R Langley

Lawrence B Snyder

Alain Martel

Omar D Lopez

Jeffrey Lee Romine

Denis R St Laurent

Van N Nguyen

Jason T Goodrich

Fukang Yang

Gan Wang

John F Kadow

Tao Wang

Zhongxing Zhang

Zhiwei Yin

Martin Duplessis

Louis Morency

Kap-Sun Yeung

Claudio F Sturino

Patrick Deroy

Jean-Eric Lacoste

Martin Tremblay

Joannie Minville

Sébastien Morin

Pierre Louis Beaulieu

Christiane Yoakim

Bruno Simoneau

Stephane Ciblat

Teddy Halmos

Yi Zhang

Jason J Marineau

Anne-Marie Faucher

Bradley C Pearce

James Gillard

David J Carini

Lee Fader

Carl Thibeault

Paul John Edwards

David C Moebius

Huiping Amy Guan

Claudio Edmundo Chuaqui

Barry L Johnson

Sebastien Morin

Mathieu Parisien

Eric Malenfant

Goran Malojcic

William Sinko

Sylvain Bernard

Zhilei Qiu

Amandine Xolin

Malay Doshi

Zhilei Qui

Claudio Sturino

Belema Makonen

Paul J Edwards

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.

Pyrrolotriazine compounds and methods of inhibiting TAM kinases

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors. 

Tricyclic alkene derivatives as HIV attachment inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors. 

Piperidine amide derivatives as HIV attachment inhibitors

Compounds of formula (I) and pharmaceutical compositions thereof: wherein AAand Aare each independently selected from the group consisting of N and CR, wherein Ris an optionally substituted heterocyclyl or an optionally substituted &#x2014;(C)alkyl-heterocyclyl, Ris an optionally substituted aryl or an optionally subsisted heteroaryl, Ris an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication. 

Inhibitors of HIV replication

Compounds of Formula (I) wherein n, R, R, R, Rand Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

Compounds of formula (I): wherein R, R, A, A, A, A, X and Y are as defined herein, are useful as inhibitors of HIV replication.

Growing community of inventors

Candiac, Canada

Clint A James